Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1296 • ACR Convergence 2024
Effectiveness of Inflammatory Arthritides Educational Modules and Potential for Improved Referral Times
Christine Kim¹, Vincent Vertalino², Karen Kruzer³ and Allen Anandarajah⁴, ¹University of Rochester, Rochester, ²University of Rochester, Hamburg, NY, ³University of Rochester, Victor, NY, ⁴University of Rochester Medical Center, Rochester, NY
Background/Purpose: Early diagnosis and treatment of inflammatory arthritides [rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)] are associated with improved patient outcomes. However,…
Abstract Number: 1339 • ACR Convergence 2024
When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
Kathleen Carluzzo¹, Erin Knight¹, Sidney May¹, Laura Bernstein², Kristen Mueller³, Clifton Bingham⁴ and Karen Schifferdecker¹, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Philadelphia, PA, ³Arthritis Foundation, Washington, DC, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: RA treatment involves an iterative approach to identifying effective medications for patients. While response varies, there is little in-depth understanding of patients’ perspectives of…
Abstract Number: 1355 • ACR Convergence 2024
Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis
Thomas Riley¹, Austin Wheeler², grant Cannon³, Sauer brian⁴, Gary Kunkel⁵, Katherine Wysham⁶, Bryant England², Kristin Wipfler⁷, Kaleb Michaud², Beth Wallace⁸, Rachel Elam⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Gail Kerr¹², Isaac Smith¹³, John Richards¹⁴, Iris Lee¹⁵, Michael March¹⁶, Scott Damrauer¹⁷, Anurag Verma¹⁷, Michael George¹⁷, Ted Mikuls² and Joshua Baker¹⁷, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Augusta University, Evans, GA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹³Duke University Hospital, Durham, NC, ¹⁴Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁵Washington University in St Louis, Saint Louis, MO, ¹⁶Children's Hospital of Philadelphia, Philadelphia, ¹⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: C-reactive protein (CRP) is often used as a biomarker for disease activity in patients with rheumatoid arthritis (RA). We evaluated whether rs1205, a common…
Abstract Number: 1371 • ACR Convergence 2024
DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis
Daniela Seelmann¹, Jiha Lee² and Devyani Misra³, ¹Beth Israel Deaconess Medical Canter, Newton, MA, ²University of Michigan, Ann Arbor, MI, ³Beth Israel Deaconess Medical Center, Boston, Boston, MA
Background/Purpose: Disease modifying anti-rheumatic drug (DMARD) use in older adults with rheumatoid arthritis (RA) is challenging due to unique geriatric issues, such as multimorbidity, polypharmacy,…
Abstract Number: 1388 • ACR Convergence 2024
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Ting Wang¹, Ryan Stultz¹, Natalia Giltiay², Christian Lood¹ and Bobby Kwanghoon Han¹, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 1713 • ACR Convergence 2024
Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Propensity Score-Matched Study Using National Veterans Affairs Data
Halie Frideres¹, Christopher Wichman², Jianghu Dong³, Punyasha Roul⁴, Yangyuna Yang², Joshua Baker⁵, Michael George⁶, Tate Johnson², Jorge Rojas⁷, Sauer brian⁸, grant Cannon⁹, Scott Matson¹⁰, Jeffrey Curtis¹¹, Ted Mikuls² and Bryant England², ¹UNMC Department of Rheumatology, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ⁴UNMC, Omaha, NE, ⁵Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Seattle VA, Mexico, Mexico, ⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁹University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁰University of Kansas, Kansas City, MO, ¹¹University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Recent RA-interstitial lung disease (RA-ILD) treatment guidelines noted a paucity of evidence on the comparative effectiveness and safety of DMARDs in RA-ILD. Previously, TNFi…
Abstract Number: 1848 • ACR Convergence 2024
Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis
Vallayyachari Kommoju¹, Sree Nethra Bulusu², Shruthi S Vembar³, Chengappa Kavadichanda⁴, Molly Thabah⁵, Christina Mary Mariaselvam² and Vir Singh Negi⁶, ¹JIPMER, Pondicherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³IGIB, Bengalore, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Inflammatory cytokines in the periphery can affect Treg stability and function by altering its molecular signatures. We aimed to characterize Treg phenotype, function and…
Abstract Number: 1909 • ACR Convergence 2024
Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Insa Mannstadt¹, Yiyuan Wu² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
Abstract Number: 2125 • ACR Convergence 2024
Strengthening Fracture Risk Prediction in Rheumatoid Arthritis: Integrating a Self-report Sarcopenia Screening Tool (SARC-F) and Fracture Risk Assessment Tool (FRAX) Scores
Ana Rodriguez-Flores¹, Ana Cecilia Bardan-Inchaustegui², Mara Ponce², Galilea Rodriguez³, Anahí Carrazco Chapa⁴, Valeria Monserrat De Hoyos-Perez⁵, Gilberto J Cervantes Charles⁵, Alma Damian Peñaloza⁵, Cinthia Maribel Cortez Lopez⁵, CASSANDRA SKINNER TAYLOR⁶, Roberto Negrete Lopez⁵, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico, ⁴Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ⁵Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁶HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of fractures due to factors such as chronic inflammation, use of glucocorticoids, and reduced muscle mass.…
Abstract Number: 2218 • ACR Convergence 2024
Association Between Frailty and Peri-Operative Inpatient Adverse Outcomes Among Patients with and Without Rheumatoid Arthritis
Ali Yazdanyar¹, Joshua Baker², Katherine Wysham³ and Michael Ward⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴NIH, Bethesda, MD
Background/Purpose: Frailty is a state reflecting a reduced physiologic reserve. There is accumulating literature on the prevalence and clinical significance of frailty in Rheumatoid Arthritis…
Abstract Number: 2235 • ACR Convergence 2024
The Updated PREVENT (Predicting Risk of CVD EVENTs) Algorithm Is Not Able to Indicate Subclinical Coronary or Carotid Atherosclerosis Better Than the Traditional Pooled Cohort Equations in Rheumatoid Arthritis
J. Alex B. Gibbons¹, Joan Bathon² and Jon Giles³, ¹Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ²Columbia University, NEW YORK, NY, ³Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with RA are at increased risk of atherosclerotic cardiovascular disease (ASCVD), yet traditional 10-year CVD risk calculators—such as the 2013 Pooled Cohort Equations…
Abstract Number: 2252 • ACR Convergence 2024
Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
Maya H. Buch¹, Patrick Verschueren², Roberto Caporali³, Thomas Huizinga⁴, Edmund V. Ekoka Omoruyi⁵, Dick de Vries⁶, Jeffrey Ritsema⁷, Francesco De Leonardis⁸ and Daniel Aletaha⁹, ¹Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁵Biostatistics, Galapagos NV, Mechelen, Belgium, ⁶Clinical Development, Galapagos BV, Leiden, Netherlands, ⁷Medical Affairs, Galapagos BV, Leiden, Netherlands, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor for the treatment of moderate to severe RA. FINCH 4 (NCT03025308) is an ongoing, open-label,…
Abstract Number: 2273 • ACR Convergence 2024
Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study
Orit Schieir¹, Marie-France Valois², Louis Bessette³, Carter Thorne⁴, Gilles Boire⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁴, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators., ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³University of Laval, Quebec City, QC, Canada, ⁴Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Increased availability of a wider array of effective RA treatments and evidence of glucocorticoid (GC)-related adverse events have prompted updated recommendations limiting GC use…
Abstract Number: 2533 • ACR Convergence 2024
Genome-wide Association of Rheumatoid Arthritis in the African Ancestry Identifies HLA Amino Acid Polymorphisms of Risk
Harrison Zhang¹, Saori Sakaue², Daniel Posner³, Jing Cui⁴, Dorris Yang⁵, Ashley Budu-Aggrey⁶, Yuk-Lam Ho³, Lauren Costa³, Rachael Matty³, Selena Huang¹, Paul Monach⁷, Kazuyoshi Ishaigaki⁸, Monika Maripuri⁷, Connor Melley⁷, Vidisha Tanukonda⁷, Rahul Sangar³, Gregory McDermott⁹, Mary Jeffway¹, Vincent Laufer¹⁰, Yukinori Okada¹¹, Ian Scott¹², S. Louis Bridges¹³, Kelly Cho³, Chuan Hong¹⁴, Jennifer E. Huffman¹⁵, Tianxi Cai¹⁶, Soumya Raychaudhuri¹ and Katherine Liao¹, and the VA Million Veteran Program, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Cambridge, MA, ³U.S. Department of Veterans Affairs, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Harvard Medical School, Cambridge, MA, ⁶Bristol Medical School, Manchester, United Kingdom, ⁷VA Boston Healthcare System, Boston, MA, ⁸Keio University School of Medicine, Tokyo, Japan, ⁹Brigham and Women's Hospital, Brookline, MA, ¹⁰Michigan Medicine, Birmingham, AL, ¹¹Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ¹²School of Medicine, Keele University, Keele, United Kingdom, ¹³Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁴Duke University, Durham, NC, ¹⁵VA Boston Healthcare System, Palo Alto, ¹⁶Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: The association between RA and the MHC is largely explained by five amino acid (AA) positions: DRB1 positions 11, 13, 71, and 74, HLA-B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].